Top MarketRank™ StocksTop MarketRank™NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $65.66 +0.66 (+1.02%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About BioMarin Pharmaceutical Stock (NASDAQ:BMRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BMRN alerts:Sign Up Key Stats Today's Range$64.07▼$66.2750-Day Range$61.93▼$70.5352-Week Range$61.15▼$99.25Volume3.97 million shsAverage Volume1.81 million shsMarket Capitalization$12.51 billionP/E Ratio39.32Dividend YieldN/APrice Target$94.20Consensus RatingModerate Buy Company OverviewBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More… BioMarin Pharmaceutical Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks100th Percentile Overall ScoreBMRN MarketRank™: BioMarin Pharmaceutical scored higher than 100% of companies evaluated by MarketBeat, and ranked 11th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on 15 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth21.29% Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 21.29% in the coming year, from $2.49 to $3.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 39.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.38.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 39.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 102.67.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 0.65. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.02% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 12.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-2.93 Percentage of Shares Shorted3.02% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 12.30%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment1.38 News SentimentBioMarin Pharmaceutical has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for BioMarin Pharmaceutical this week, compared to 9 articles on an average week.Search InterestOnly 4 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows8 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $350,301.00 in company stock.Percentage Held by InsidersOnly 1.85% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Stock News HeadlinesCan BioMarin Stock Live Up to Wall Street’s High Expectations?BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?November 22, 2024 | marketbeat.comAre BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?December 11, 2024 | uk.finance.yahoo.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 21, 2024 | Crypto Swap Profits (Ad)BioMarin Pharmaceutical: Undervalued Opportunity with Potential for Margin Expansion and Strategic GrowthDecember 5, 2024 | markets.businessinsider.comRBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)November 28, 2024 | markets.businessinsider.comWhy Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Healthcare Stocks in 2024?November 27, 2024 | insidermonkey.comCan BioMarin Stock Live Up to Wall Street's High Expectations?November 22, 2024 | msn.comJefferies Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)November 21, 2024 | markets.businessinsider.comSee More Headlines BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $96.42 at the beginning of the year. Since then, BMRN stock has decreased by 31.9% and is now trading at $65.66. View the best growth stocks for 2024 here. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings results on Tuesday, October, 29th. The biotechnology company reported $0.55 earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by $0.23. The business's revenue for the quarter was up 28.4% compared to the same quarter last year. Who are BioMarin Pharmaceutical's major shareholders? Top institutional investors of BioMarin Pharmaceutical include Primecap Management Co. CA (9.90%), Geode Capital Management LLC (1.71%), Charles Schwab Investment Management Inc. (0.74%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.46%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Richard A Meier, Jeffrey Robert Ajer, Brian Mueller, Charles Greg Guyer, George Eric Davis, V Bryan Lawlis, Erin Burkhart, Mark J Alles and Dennis Slamon. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Incyte (INCY), NVIDIA (NVDA), Meta Platforms (META), First Solar (FSLR), (MDVN) (MDVN) and Broadcom (AVGO). Company Calendar Last Earnings10/29/2024Today12/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,401Year Founded1997Price Target and Rating Average Stock Price Target$94.20 High Stock Price Target$122.00 Low Stock Price Target$65.00 Potential Upside/Downside+43.5%Consensus RatingModerate Buy Rating Score (0-4)2.74 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)$1.67 Trailing P/E Ratio39.32 Forward P/E Ratio26.37 P/E Growth0.65Net Income$167.65 million Net Margins11.71% Pretax Margin14.22% Return on Equity8.53% Return on Assets6.40% Debt Debt-to-Equity Ratio0.11 Current Ratio4.27 Quick Ratio2.62 Sales & Book Value Annual Sales$2.75 billion Price / Sales4.55 Cash Flow$1.78 per share Price / Cash Flow36.88 Book Value$26.29 per share Price / Book2.50Miscellaneous Outstanding Shares190,583,000Free Float187,057,000Market Cap$12.51 billion OptionableOptionable Beta0.29 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:BMRN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.